To further test the clinical relevance of Sunitinib‐mediated inhibition of tumor PD‐L1 and subsequent immune surveillance, we utilized combination therapeutic strategy by cotreating Sunitinib and CTLA‐4 mAb in both melanoma and NSCLC immune competent mice. Here, CTLA4 is linked to neoplasm.